Abeome Corporation has signed a research collaboration agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome’s proprietary AbeoMouse platform.
“We are very pleased to collaborate with the CDC using our proprietary antibody discovery platform, AbeoMouse, for the rapid discovery of monoclonal antibodies. It is our hope that antibodies emerging from this collaboration may have significant diagnostic and therapeutic potential in the battle against Zika,” stated Dr. Richard A. Shimkets, president and chief executive officer of Abeome Corporation.
The collaborative agreement calls for the generation of novel monoclonal antibodies specifically recognizing the Zika virus, which will be validated across related viruses for diagnostic purposes, and in cell culture and animal models of Zika infection for therapeutic potential.
Abeome’s transgenic AbeoMouse platform enables the selection of desirable functional antibodies directly from the immune system of an immunized mouse. Traditional technology typically requires the screening of thousands of antibodies to find a few with drug-like properties. The direct probing of AbeoMouse antibody producing B-cells following immunization rapidly reveals single B-cells producing high affinity antibodies that bind to the target protein but not related proteins.
The Zika virus, which is spread to people primarily through the bite of an infected Aedes species mosquito, is an impending threat to America’s borders, with over 5000 cases now reported in the continental United States. Zika virus infection has been associated with Guillain-Barré Syndrome, and infection during pregnancy has been associated with microcephaly and other severe fetal brain defects. However, high evolutionary conservation between Zika and other flaviviruses such as West Nile, Dengue and Yellow Fever have made the development of rapid antibody-based tests specifically for Zika infection particularly challenging.
Abeome is a privately held preclinical stage antibody discovery company with a pipeline of novel monoclonal antibody therapeutic candidates. Abeome’s objective is to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales.